Ardent Health

ARDT · NYSE

$12.12+$0.43 (+3.68%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.69

ARDT analyst rating

BuyConsensus of 12 analysts over the last 12 months. 58% rate it a buy.

Strong buy0
Buy7
Hold4
Underperform1
Sell0

12-month price target · 14 analysts

Average $13.17 (+8.6% upside)

Low: $10.60
Now: $12.12
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

ARDT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BMO Capital	Sep 23, 2026	Initiates	Market Perform	$11.00	41%
Leerink Partners	Sep 18, 2026	Maintains	Outperform	$14.00	55%
RBC Capital	Aug 10, 2026	Maintains	Outperform	$12.00 → $13.00	57%
Truist Securities	Aug 6, 2026	Maintains	Buy	$12.00 → $13.00	67%
Guggenheim	Aug 6, 2026	Maintains	Buy	$13.00 → $14.00	66%
Truist Securities	Jul 14, 2026	Maintains	Buy	$13.00 → $12.00	67%
RBC Capital	Jul 9, 2026	Maintains	Outperform	$13.00 → $12.00	57%
UBS	May 7, 2026	Maintains	Buy	$13.00 → $13.50	64%
RBC Capital	Mar 10, 2026	Maintains	Outperform	$14.00 → $13.00	57%
Leerink Partners	Mar 6, 2026	Maintains	Outperform	$16.00 → $15.00	55%

The case for and against

Updated Oct 17, 2026

Bull case

Ardent Health is well positioned because its 2Q26 adjusted EBITDA beat expectations despite softer surgical volumes, supported by a successful payer contract renegotiation, accelerated IMPACT savings, and meaningful labor leverage as contract labor fell 42% year over year to 2.2% of SWB. Its outlook is strengthened by service line rationalization that shifts lower-margin ENT and ophthalmology cases out of the hospital, while the CMS inpatient-only list impact was limited to just $1-2MM for the quarter and volume trends improved in June and July. Management also sees manageable exchange headwinds versus peers, stable denial trends, 10.4% professional fee growth decelerating from 12.9%, and 2026 guidance of $6.4B-$6.7B revenue with $485M-$535M EBITDA, indicating durable operating momentum and margin expansion potential.

Bear case

Ardent Health is facing a negative fundamental outlook because volume softness is pressuring earnings while management must lean on cost cuts and payer renegotiations to defend margins. Although 2026 IMPACT savings were raised to at least $70MM and the June 1 contract renewal may add $5-10MM, these benefits only partially offset roughly $25MM of volume-related earnings pressure from 2Q and a softer back-half outlook, especially as inpatient surgeries fell 7.5% and total surgeries and admissions remained below expectations. The business also carries material downside risk from Medicare and other reimbursement exposure, labor cost and availability pressures, heavy lease dependence, and concentration in Texas and Oklahoma, leaving execution risk high if ambulatory growth and organic volume recovery do not materialize.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.